Obesity and Cancer: Clinical Epidemiology

Handbook of Obesity: Epidemiology, Etiology, and Physiopathology: Volume 1, Third Edition

Volumn 1, Issue , 2014, Pages 561-572

  Renehan, Andrew G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937819076     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16473-56     Document Type: Chapter

References (100)

1. Hippocrates of Kos. http://www.platos-academy.com/archives/hippocrates.html. Accessed August 28, 2012.
2. Thomas R. The Modern Practice of Physic. New York: Collins & Co, 1811.
3. IARC. International Agency for Research in Cancer. In Vainio H, Bianchini F, eds. Weight Control and Physical Activity. Lyon: IARC Press, 2002.
4. WCRF. World Cancer Reserach Fund. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. 2nd ed. Washington: American Institute for Cancer Research, 2007.
5. Renehan A, Tyson M, Egger M, et al. Body mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
6. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012;23(7):1665-71.
7. Koebnick C, Michaud D, Moore SC, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2008;17:1214-21.
8. Moore SC, Rajaraman P, Dubrow R, et al. Height, body mass index, and physical activity in relation to glioma risk. Cancer Res 2009;69:8349-55.
9. Lerro CC, McGlynn KA, Cook MB. A systematic review and meta-analysis of the relationship between body size and tes-ticular cancer. Br J Cancer 2010;103:1467-74.
10. Druesne-Pecollo N, Touvier M, Barrandon E, et al. Excess body weight and second primary cancer risk after breast cancer: A systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat 2012;135:647-54.
11. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: New perspectives. Annu Rev Med 2010;61:301-16.
12. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: The Women’s Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
13. Feigelson HS, Jonas CR, Teras LR, et al. Weight gain, body mass index, hormone replacement therapy, and postmeno-pausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004;13:220-4.
14. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: Findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004;111:762-71.
15. Mellemkjaer L, Bigaard J, Tjonneland A, et al. Body composition and breast cancer in postmenopausal women: A Danish prospective cohort study. Obesity (Silver Spring) 2006; 14:1854-62.
16. Tehard B, Clavel C, F. Several anthropometric measurements and breast cancer risk: Results of the E3N cohort study. Int J Obes 2006;30:156-63.
17. Ahn J, Schatzkin A, Lacey JV, Jr., et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007;167:2091-102.
18. Crosbie EJ, Zwahlen M, Kitchener HC, et al. Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:3119-30.
19. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 2012;9(4):e1001200. PubMed PMID: 22606070. Pubmed Central PMCID: 3317899. Epub 2012/05/19. eng
20. Renehan AG. The epidemiology of overweight/obesity and cance risk. In McTiernan A, ed. Physical Activity, Dietary Calorie Restriction, and Cancer. New York: Springer, 2010.
21. Smith L, Brinton LA, Spitz MR, et al. Body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst 2012;104:778-89.
22. Steffen A, Schulze MB, Pischon T, et al. Anthropometry and esophageal cancer risk in the European prospective investiga-tion into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2009;18:2079-89.
23. Jiao L, Berrington de Gonzalez A, Hartge P, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: A pooled study of seven prospective cohorts. Cancer Causes Control 2010;21:1305-14.
24. Hill AB. The environment and disease: Association or causation? Proc R Soc Med 1965;58:295-300.
25. Hofler M. The Bradford Hill considerations on causality: A counterfactual perspective. Emerg Themes Epidemiol 2005;2:11.
26. Renehan AG, Egger M, Zwahlen M. Body mass index and cancer risk: The evidence for causal association. The Open Obesity Journal 2010;2:12-22.
27. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011;11:886-95.
28. Sjostrom L, Gunmmessson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidences in Sweden (Swedish Obese Subjects): A prospective, controlled intervention trial. Lancet Oncology 2009;10(7):653-62.
29. Renehan AG. Bariatric surgery, weight reduction and cancer prevention. Lancet Oncol 2009;10:640-1.
30. Renehan AG, Soerjomataram I, Tyson M, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer 2010;126:692-702.
31. Smith GD, Ebrahim S. Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42.
32. Smith GD, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian ran-domization. Ann Med 2008;40:524-41.
33. Tao MH, Cai Q, Zhang ZF, et al. Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2007;16:943-9.
34. Wen W, Cai Q, Xiang YB, et al. The modifying effect of C-reactive protein gene polymorphisms on the association between central obesity and endometrial cancer risk. Cancer 2008;112:2409-16.
35. Lurie G, Gaudet MM, Spurdle AB, et al. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One 2011;6:e16756.
36. Lewis SJ, Murad A, Chen L, et al. Associations between an obesity-related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One 2010;5:e13485.
37. Tenesa A, Campbell H, Theodoratou E, et al. Common genetic variants at the MC4R locus are associated with obesity, but not with dietary energy intake or colorectal cancer in the Scottish population. Int J Obes (Lond) 2009;33:284-8.
38. Brennan P, McKay J, Moore L, et al. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. Int J Epidemiol 2009;38:971-5.
39. Kilpelainen TO, Zillikens MC, Stancakova A, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet 2011;43:753-60.
40. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42:937-48.
41. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
42. Parr CL, Batty GD, Lam TH, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424,519 participants. Lancet Oncol 2010;11:741-52.
43. Bessonova L, Marshall SF, Ziogas A, et al. The association of body mass index with mortality in the California Teachers Study. Int J Cancer 2011;129:2492-501.
44. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ 2007;335(7630):1134-49. PubMed PMID: 17986716.
45. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2011;4:486-501.
46. Colangelo LA, Gapstur SM, Gann PH, et al. Colorectal cancer mortality and factors related to the insulin resistance syn-drome. Cancer Epidemiol Biomarkers Prev 2002;11:385-91.
47. Haydon AM, Macinnis RJ, English DR, et al. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 2006;55:62-7.
48. Prizment AE, Flood A, Anderson KE, et al. Survival of women with colon cancer in relation to precancer anthropometric characteristics: The Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 2010;19:2229-37.
49. Campbell PT, Newton CC, Dehal AN, et al. Impact of body mass index on survival after colorectal cancer diagnosis: The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012;30:42-52.
50. Tamakoshi K, Wakai K, Kojima M, et al. A prospective study of body size and colon cancer mortality in Japan: The JACC Study. Int J Obes Relat Metab Disord 2004;28:551-8.
51. Batty GD, Shipley MJ, Kivimaki M, et al. Obesity and overweight in relation to liver disease mortality in men: 38 year follow-up of the original Whitehall study. Int J Obes (Lond) 2008;32:1741-4.
52. Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev 2012;21:1244-59.
53. Crosbie EJ, Roberts C, Qian W, et al. Body mass index does not influence post-treatment survival in early stage endome-trial cancer: Results from the MRC ASTEC trial. Eur J Cancer 2012;48:853-64.
54. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H. Diabetes and cancer (2): Evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012;55(6):1619-32. PubMed PMID: 22476948. Eng.
55. Niraula S, Ocana A, Ennis M, et al. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res Treat 2012;134:769-81.
56. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627-35.
57. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
58. Suissa S, Pollak M, Spitzer WO, et al. Body size and breast cancer prognosis: A statistical explanation of the discrepancies. Cancer Res 1989;49:3113-6.
59. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. J Clin Oncol 2012;30:164-71.
60. Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011;29:25-31.
61. Caan BJ, Kwan ML, Shu XO, et al. Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev 2012;21:1260-71.
62. Greenman CG, Jagielski CH, Griggs JJ. Breast cancer adjuvant chemotherapy dosing in obese patients: Dissemination of information from clinical trials to clinical practice. Cancer 2008;112:2159-65.
63. Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemother-apy for breast cancer. Eur J Cancer 2007;43:544-8.
64. Carroll J, Protani M, Walpole E, Martin JH. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: A systematic review. Breast Cancer Res Treat 2012;136(2):323-30. PubMed PMID: 22918525. Eng.
65. Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 2010;28:3411-5.
66. Pfeiler G, Konigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011;29:2653-9.
67. Folkerd EJ, Dixon JM, Renshaw L, et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 2012;30:2977-80.
68. Joshu CE, Mondul AM, Menke A, et al. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila) 2011;4:544-51.
69. Doria-Rose VP, Newcomb PA, Morimoto LM, et al. Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States). Cancer Causes Control 2006;17:63-70.
70. Asghari-Jafarabadi M, Hajizadeh E, Kazemnejad A, et al. Site-specific evaluation of prognostic factors on survival in Iranian colorectal cancer patients: A competing risks survival analysis. Asian Pac J Cancer Prev 2009;10:815-21.
71. Baade PD, Meng X, Youl PH, et al. The impact of body mass index and physical activity on mortality among patients with colorectal cancer in Queensland, Australia. Cancer Epidemiol Biomarkers Prev 2011;20:1410-20.
72. Volkova E, Willis JA, Wells JE, et al. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 2011;104:51-9.
73. Chern H, Chou J, Donkor C, et al. Effects of obesity in rectal cancer surgery. J Am Coll Surg 2010;211:55-60.
74. Hines RB, Shanmugam C, Waterbor JW, et al. Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer 2009;115:5798-806.
75. Ballian N, Yamane B, Leverson G, et al. Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma. Ann Surg Oncol 2010;17:1606-13.
76. Moon HG, Ju YT, Jeong CY, et al. Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol 2008;15:1918-22.
77. Sinicrope FA, Foster NR, Sargent DJ, et al. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res 2010;16:1884-93.
78. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from Intergroup Trial 0114. J Clin Oncol 2004;22:648-57.
79. Pathak S, Tang JM, Terlizzo M, et al. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases. Eur J Surg Oncol 2010;36:52-7.
80. van Vledder MG, Levolger S, Ayez N, et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012;99:550-7.
81. Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59:341-7.
82. Simkens LH, Koopman M, Mol L, et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer 2011;47:2560-7.
83. Everett E, Tamimi H, Greer B, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2003;90:150-7.
84. Martra F, Kunos C, Gibbons H, et al. Adjuvant treatment and survival in obese women with endometrial cancer: An international collaborative study. Am J Obstet Gynecol 2008;198:89 e1-8.
85. Mauland KK, Trovik J, Wik E, et al. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer 2011;104:921-6.
86. Munstedt K, Wagner M, Kullmer U, et al. Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control 2008;19:909-16.
87. Temkin SM, Pezzullo JC, Hellmann M, et al. Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol 2007;30:8-14.
88. Kizer NT, Thaker PH, Gao F, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 2011;117:948-56.
89. Paes JE, Hua K, Nagy R, et al. The relationship between body mass index and thyroid cancer pathology features and out-comes: A clinicopathological cohort study. J Clin Endocrinol Metab 2010;95:4244-50.
90. Brookman-May S, Kendel F, Hoschke B, et al. Impact of body mass index and weight loss on cancer-specific and overall survival in patients with surgically resected renal cell carcinoma. Scand J Urol Nephrol 2011;45:5-14.
91. Haferkamp A, Pritsch M, Bedke J, et al. The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU Int 2008;101:1243-6.
92. Jeon HG, Jeong IG, Lee JH, et al. Prognostic value of body mass index in Korean patients with renal cell carcinoma. J Urol 2010;183:448-54.
93. Parker AS, Lohse CM, Cheville JC, et al. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 2006;68:741-6.
94. Schrader AJ, Rustemeier J, Rustemeier JC, et al. Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol 2009;135:1693-9.
95. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2012;5:901-10.
96. Goodwin PJ. Commentary on: Effect of obesity on survival in women with breast cancer: Systematic review and meta-analysis (Melinda Protani, Michael Coory, Jennifer H. Martin). Breast Cancer Res Treat 2010;123:637-40.
97. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005;16:285-94.
98. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011;365:1375-83.
99. Kong CY, Nattinger KJ, Hayeck TJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: Estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev 2011;20:2450-6.
100. Zhai R, Chen F, Liu G, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 2010;28:2445-51.